Table 1.
Participant demographics and baseline characteristics (randomized analysis set)
| Variable | DAPA + MET (n = 314) |
DAPA + SAXA + MET
(n = 312) |
GLIM + MET
(n = 313) |
Total
(n = 939) |
|---|---|---|---|---|
| Women (%) | 112 (35.7) | 122 (39.1) | 105 (33.5) | 339 (36.1) |
| Age (years) | 57.4 (9.4) | 59.2 (7.9) | 58.6 (8.4) | 58.4 (8.6) |
| Weight (kg) | 97.7 (18.9) | 95.3 (17.4) | 97.3 (17.9) | 96.8 (18.1) |
| BMI (kg/m2) | 33.1 (5.2) | 32.5 (5.1) | 33.0 (5.1) | 32.9 (5.1) |
| SBP (mm Hg) | 138.4 (14.3) | 138.8 (14.1) | 138.8 (13.2) | 138.6 (13.9) |
| Duration of type 2 diabetes (years) | 6.9 (5.2) | 7.3 (5.9) | 6.7 (5.1) | 7.0 (5.4) |
| HbA1c (%) | 8.3 (0.7) | 8.3 (0.7) | 8.3 (0.8) | 8.3 (0.7) |
| FPG (mmol/L) | 10.6 (2.3) | 10.5 (2.0) | 10.4 (2.1) | 10.5 (2.1) |
| eGFR (MDRD) (mL/min/1.73m2) | 87.2 (19.4) | 88.0 (19.6) | 86.0 (17.5) | 87.1 (18.9) |
| C‐peptide (ng/mL) | 0.93 (0.36) | 0.92 (0.37) | 0.93 (0.34) | 0.93 (0.36) |
| History of hypertension (%) | 251 (79.9) | 253 (81.1) | 256 (81.8) | 760 (80.9) |
| Antihypertensive drug usea | ||||
|---|---|---|---|---|
| n = 313 | n = 312 | n = 312 | n = 937 | |
| ACE inhibitors (plain or combinations) | 143 (45.7) | 163 (52.2) | 164 (52.6) | 470 (50.2) |
| Angiotensin II antagonists (plain or combinations) | 96 (30.7) | 70 (22.4) | 74 (23.7) | 240 (25.6) |
| Beta‐blockers (selective) | 114 (36.4) | 110 (35.3) | 104 (33.3) | 328 (35.0) |
| Thiazides (plain) | 39 (12.5) | 41 (13.1) | 48 (15.4) | 128 (13.7) |
Data are presented as mean (SD) or number (%).
Abbreviations: ACE, angiotensin‐converting‐enzyme; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLIM, glimepiride; HbA1c, glycated haemoglobin; MDRD, Modification of Diet in Renal Disease; MET, metformin; SAXA, saxagliptin; SBP, systolic blood pressure; SD, standard deviation.
a
Includes medications initiated after double‐blind treatment initiation or prior to double‐blind treatment initiation, but continued during the double‐blind treatment phase. Data are from the safety analysis set.